New drug cocktail aims to shrink Hard-to-Treat stomach tumors
NCT ID NCT07507526
First seen Apr 24, 2026 · Last updated Apr 25, 2026 · Updated 1 time
Summary
This study tests whether a combination of three drugs (disitamab vedotin, tunlametinib, and a PD-1 antibody) can shrink tumors in people with advanced HER2-positive gastric cancer who have already tried at least two other treatments. About 76 adults will receive the drugs intravenously and orally, with regular checkups and scans. The main goal is to see how many patients experience tumor shrinkage, while also monitoring side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.